Novo Nordisk A/S (NYSE: NVO) announced a new partnership with Aspen Pharmacare to establish human insulin production in South Africa.
Aspen Pharmacare will manufacture human insulin in South Africa, specifically for export to African nations, through a cost-effective government tender system.
Under this contract, Novo expects the production of 16 million insulin vials next year, equivalent to the yearly consumption of 1.1 million people.
Also Read: Popular Obesity Drugs For Dementia, Addiction Treatment? Researchers Explore Potential.
By 2026, this ...